Board of Directors
Charles J. Casamento, MBA, Chairman of the Board
Since 2007 Mr. Casamento has been executive director and principal of The Sage Group, a health care advisory group. He was president and CEO of Osteologix from October 2004 until April 2007. Mr. Casamento was the founder of Questcor Pharmaceuticals where he was president, CEO and chairman. In 2014 Questcor was acquired by Mallinckrodt for approximately $6 Billion. At RiboGene Inc. he was president, CEO and chairman and he was also co-founder, president and CEO of Indevus (formerly Interneuron Pharmaceuticals). Indevus was eventually acquired by Endo for approximately $800 Million. He has held senior management positions at Genzyme Corporation, where he was Senior Vice President and General Manager for Biochemicals and Pharmaceuticals, American Hospital Supply, where he was Vice President of Business Development for the Critical Care Division, Johnson & Johnson, Hoffmann-LaRoche and Sandoz. During his career he has been a Director of nine other pharmaceutical/biotechnology companies and has been on the board of two not for profit organizations. He holds a bachelor’s degree in Pharmacy from Fordham University and an M.B.A. from Iona College. Mr. Casamento also serves as the Chairman of the company’s Audit Committee.
Paul Kelly, MBA, Director
Paul Kelly has been actively involved as an analyst, consultant and investor in the biotechnology sector for the past twenty years. He began as an equity analyst at Mabon Securities in 1993, and later served in the same capacity at UBS Securities, Volpe, Brown, Whalen, ING Securities, and Merrill Lynch. Mr. Kelly was named to the inaugural Fortune Magazine All Star Analyst Team in 2000. Since 2007, Mr. Kelly has engaged in consulting for private and public biotechnology companies and for hedge funds. He currently manages his own investments and continues his industry consulting activities. Mr. Kelly holds an A.B. in biochemistry from Brown University, attended the University of Rochester School of Medicine, and received an M.B.A in finance from the William E. Simon School at the University of Rochester.
Maged Shenouda, R.Ph, MBA, Director
Mr. Shenouda has over 25 years of biotechnology and equity research experience. Most recently, he was head of business development and licensing at Retrophin, Inc. from January 2014 to November 2014. From January 2012 to September 2013, he was managing director, head of east coast operations at Blueprint Life Science Group. From June 2010 to November 2011, Mr. Shenouda was managing director, senior biotechnology analyst at Stifel Nicolaus. He also held senior level positions in equity research at UBS and JP Morgan, and worked in sell side equity research at Citigroup and Bear Stearns where he covered many U.S. and E.U. pharmaceutical companies. Before beginning his career on Wall Street, Mr. Shenouda was a management consultant with PricewaterhouseCoopers Pharmaceutical Consulting and also spent time in pharmaceutical sales, having worked as a hospital representative and managed care specialist for Abbott Laboratories’ pharmaceutical products division. Mr. Shenouda currently serves as independent director for Protea Biosciences and AzurRx Biopharma. He earned a B.S. in pharmacy from St. John's University and is a registered pharmacist in New Jersey and California. He also received an M.B.A from Rutgers Graduate School of Management.
Sergio Traversa, PharmD, MBA, Chief Executive Officer and Interim Chief Financial Officer
Before joining Relmada, Dr. Traversa was the co-founder and CEO of Medeor Inc. a spinoff pharmaceutical company from Cornell University. Dr. Traversa has over twenty-five years of experience in the healthcare sector in the United States and Europe, ranging from management positions in the pharmaceutical industry to investing and strategic advisory roles. He has held financial analyst, portfolio management and strategic advisory positions at large U.S. investment firms specializing in healthcare, including Mehta and Isaly and Mehta partners, ING Barings, Merlin BioMed and Rx Capital. Dr. Traversa was a founding partner of Ardana Capital, a pharmaceutical and biotechnology investment advisory firm. In Europe, he held the position of Area Manager for Southern Europe of Therakos Inc., a cancer and immunology division of Johnson & Johnson. Prior to Therakos, Dr. Traversa was at Eli Lilly, where he served as Marketing Manager of the Hospital Business Unit. He was also a member of the CNS team at Eli Lilly, where he participated in the launch of Prozac and the early development of Zyprexa and Cymbalta. Dr. Traversa started his career as a sales representative at Farmitalia Carlo Erba, the largest pharmaceutical company in Italy later sold to Pharmacia and now part of Pfizer. Dr. Traversa holds a Laurea degree in Pharmacy from the University of Turin (Italy) and an MBA in Finance and International Business from the New York University Leonard Stern School of Business.